No. 3: The year of big pharma In the past five years, big
cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.
Not exact matches
As pressure mounted over the
pharmaceutical giant's rising insulin prices, investors drove its
stock down by a third, fearing that policymakers would
cap price tags and hurt profits.
One of those
stocks is Actavis, the large -
cap pharmaceutical company that has tripled in returns over the last three years.
Adamas
Pharmaceuticals Inc (NASDAQ: ADMS), a small -
cap pharmaceutical company that develops therapies to treat chronic neurologic disorders, is a «misunderstood»
stock that has a potential upside of four times, Kerrisdale Capital said in a new report.
Brian Feroldi (Supernus
Pharmaceuticals): Most small -
cap biotech
stocks barely generate any revenue at all, let alone profits.
Dollar Bill plans a big short position on a
pharmaceutical company
stock, but not everyone at Axe
Cap approves.
I scour more than 200 advisories and research reports to select the top recommendations including growth
stocks, value
stocks, technology, small -
caps, biotech,
pharmaceuticals, funds, ETFs and more.
Selections run the full range of opportunities: growth
stocks, value
stocks, technology, small -
caps, biotech,
pharmaceuticals, mutual funds, ETFs and more.